CTI BioPharma (CTIB) Pacritinib a Real Threat to Ruxolitinib, Roth Capital Says
Tweet Send to a Friend
Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating and $4.50 price target on CTI BioPharma (NASDAQ: CTIC) following ASCO ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
